27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Tau accumulation in patients with Alzheimer's disease tracks closely with cognitive decline and plays a role in the later stages of disease progression. 4 key findings →
Design: clinical trial Participants: 108 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer. 5 key findings →
Participants: 4,365 Evidence: high
Full summary, score breakdown and related studies → Original source
Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. 5 key findings →
Participants: 3,370 Evidence: high
Full summary, score breakdown and related studies → Original source
This clinical trial evaluates the efficacy and safety of a 6-week course of daily neuroAD™ therapy. 4 key findings →
Participants: 131 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). 4 key findings →
Participants: 182 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. 4 key findings →
Participants: 577 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials. 4 key findings →
Design: randomized controlled trial Participants: 620 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Between May 18, 2021, and Sept 8, 2023, 9981 participants were screened, of whom 3808 were randomly assigned; 1855 in evoke (semaglutide, n=928; placebo, n=927) and 1953 in evoke+ (semaglutide, n=976; placebo, n=977). 5 key findings →
Design: clinical trial Participants: 928 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Deep brain stimulation (DBS) is used to modulate the activity of dysfunctional brain circuits. 4 key findings →
Design: post-hoc analysis Participants: 42 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
PE-treated patients performed significantly better than placebo for the co-primary endpoints: change from baseline of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL; P = .03; 52% less decline) with a trend for Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; P = .06; 66% less decline) scores at month 14. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). 4 key findings →
Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer's disease (AD), the Alphase study. 4 key findings →
Design: longitudinal study Participants: 109 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer's disease. 4 key findings →
Participants: 37 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Huperzine A is a Chinese herb extract used for Alzheimer's disease. 4 key findings →
Design: meta-analysis Participants: 1,823 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most common cause of dementia. 4 key findings →
Design: systematic review Participants: 87 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer's disease (AD). 4 key findings →
Participants: 51 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The treatment of ischaemic stroke with neuroprotective drugs has been unsuccessful, and whether these compounds can be used to reduce disability after recurrent stroke is unknown. 4 key findings →
Participants: 20,332 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There are 9.9 million new cases of dementia in the world every year. 4 key findings →
Design: randomized controlled trial Participants: 52 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. 4 key findings →
Design: clinical trial Participants: 399 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids (omega3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cardiovascular risk factors and a history of vascular disease can increase the risk of Alzheimer's disease (AD). 4 key findings →
Design: randomized controlled trial Participants: 156 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). 4 key findings →
Design: clinical trial Participants: 1,496 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran. 2 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In cell culture experiments, flupirtine maleate (FLU), a triaminopyridine compound, was able to protect neuronal cells from apoptotic cell death induced by prion protein fragments and beta-amyloid peptides. 4 key findings →
Participants: 13 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Poor vitamin D nutrition is linked with dementia, but vitamin D has not been tested in a randomized controlled trial (RCT) in Alzheimer's disease (AD). 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →